Cargando…

Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis

BACKGROUND AND OBJECTIVES: To increase the validity of biomarker measures in multiple sclerosis (MS), factors affecting their concentration need to be identified. Here, we test whether the volume of distribution approximated by the patients' estimated blood volume (BV) and body mass index (BMI)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yalachkov, Yavor, Schäfer, Jan Hendrik, Jakob, Jasmin, Friedauer, Lucie, Steffen, Falk, Bittner, Stefan, Foerch, Christian, Schaller-Paule, Martin Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673750/ https://www.ncbi.nlm.nih.gov/pubmed/36316116 http://dx.doi.org/10.1212/NXI.0000000000200045

Ejemplares similares

Analysis of CSF D-Dimer to Identify Intrathecal Fibrin-Driven Autoimmunity in Patients With Multiple Sclerosis
por: Schaller-Paule, Martin A., et al.
Publicado: (2022)

C-Reactive Protein Levels and Gadolinium-Enhancing Lesions Are Associated With the Degree of Depressive Symptoms in Newly Diagnosed Multiple Sclerosis
por: Yalachkov, Yavor, et al.
Publicado: (2021)

Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2020)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

A Proposal for a Patient-Oriented Five-Dimensional Approach for Surveillance and Therapy in Multiple Sclerosis
por: Yalachkov, Yavor, et al.
Publicado: (2017)

Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients
por: Halbgebauer, Rebecca, et al.
Publicado: (2022)

Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels
por: Camara-Lemarroy, Carlos, et al.
Publicado: (2022)

Emergence delirium and postoperative delirium associated with high plasma NfL and GFAP: an observational study
por: Liu, Xingyang, et al.
Publicado: (2023)

Measurement of D-dimer in cerebrospinal fluid using a luminescent oxygen channeling immunoassay
por: Kohlhase, Konstantin, et al.
Publicado: (2022)

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus
por: Margraf, Nils G., et al.
Publicado: (2023)

Patients with chronic autoimmune demyelinating polyneuropathies exhibit cognitive deficits which might be associated with CSF evidence of blood-brain barrier disturbance
por: Yalachkov, Yavor, et al.
Publicado: (2020)

Combined use of CSF NfL and CSF TDP‐43 improves diagnostic performance in ALS
por: Kasai, Takashi, et al.
Publicado: (2019)

Sex Differences in Behavioral Symptoms and the Levels of Circulating GFAP, Tau, and NfL in Patients With Traumatic Brain Injury
por: Sass, Dilorom, et al.
Publicado: (2021)

Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients
por: Ferrari, Federica, et al.
Publicado: (2023)

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Foerch, Christian, et al.
Publicado: (2020)

A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort
por: van Dam, Maureen, et al.
Publicado: (2023)

Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
por: Baiardi, Simone, et al.
Publicado: (2022)

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
por: Gust, Juliane, et al.
Publicado: (2022)

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Schindler, Patrick, et al.
Publicado: (2021)

Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19
por: Bark, Lovisa, et al.
Publicado: (2023)

CSF and Blood Levels of GFAP in Alexander Disease
por: Jany, Paige L., et al.
Publicado: (2015)

Plasma UCHL1, GFAP, Tau, and NfL Are Not Different in Young Healthy Persons With Mild COVID-19 Symptoms Early in the Pandemic: A Pilot Study
por: Rogatzki, Matthew J., et al.
Publicado: (2023)

NfL and pNfH are increased in Friedreich’s ataxia
por: Hayer, Stefanie Nicole, et al.
Publicado: (2020)

Visual Search in Naturalistic Scenes Reveals Impaired Cognitive Processing Speed in Multiple Sclerosis
por: Gehrig, Johannes, et al.
Publicado: (2022)

Cognitive Impairment in Multiple Sclerosis Is Reflected by Increased Susceptibility to the Sound-Induced Flash Illusion
por: Yalachkov, Yavor, et al.
Publicado: (2019)

Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community‐based sample of 70‐year‐olds
por: Dittrich, Anna, et al.
Publicado: (2022)

Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting
por: Youssef, Priscilla, et al.
Publicado: (2023)

Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis
por: Cruz-Gomez, Álvaro J., et al.
Publicado: (2021)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics
por: Kojima, Yuta, et al.
Publicado: (2021)

The Use of Biologics in NFL Athletes: An Expert Consensus of NFL Team Physicians
por: Murray, Iain R., et al.
Publicado: (2023)

Blood Levels of Glial Fibrillary Acidic Protein (GFAP) in Patients with Neurological Diseases
por: Mayer, Christoph A., et al.
Publicado: (2013)

Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management
por: Yalachkov, Yavor, et al.
Publicado: (2022)

Increased CSF NFL in Non-demented Parkinson’s Disease Subjects Reflects Early White Matter Damage
por: Papuć, Ewa, et al.
Publicado: (2020)

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
por: Hansson, Oskar, et al.
Publicado: (2017)

Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria
por: Kern, Daniela, et al.
Publicado: (2022)

Effect of Posterior Glenoid Labral Tears at the NFL Combine on Future NFL Performance
por: Murphy, Colin P., et al.
Publicado: (2018)

Epidemiology of Navicular Injury at the NFL Combine and Their Impact on an Athlete’s Prospective NFL Career
por: Vopat, Bryan, et al.
Publicado: (2017)

Can NFL Combine Results be Used to Estimate NFL Defensive Players Longevity?
por: Pollock, Jordan Riley, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kbk9k9mf9ff9ep7dmelquelj88